We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

65 hedge funds and large institutions have $159M invested in CERo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

25% more funds holding

Funds holding: 52 → 65 (+13)

7% more capital invested

Capital invested by funds: $149M → $159M (+$10.2M)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

Holders
65
Holders Change
+13
Holders Change %
+25%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
16
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$11.8M
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$4.71M
3
MF
Magnetar Financial
Illinois
+$3.2M
4
Marshall Wace
Marshall Wace
United Kingdom
+$2.14M
5
MC
Meteora Capital
Florida
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$7.51M
2
HIM
HGC Investment Management
Ontario, Canada
-$5.04M
3
LA
Linden Advisors
New York
-$4.71M
4
WP
Woodline Partners
California
-$3.01M
5
CL
CSS LLC
Illinois
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$13.1M +$11.8M +585 +900%
SCM
2
Saba Capital Management
New York
$12.2M +$806K +40 +7%
HCM
3
Highbridge Capital Management
New York
$11M +$624K +31 +6%
Marshall Wace
4
Marshall Wace
United Kingdom
$8.58M +$2.14M +106 +33%
PC
5
Periscope Capital
Ontario, Canada
$7.59M +$1.53M +76 +25%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$7.55M +$121K +6 +2%
HSBC Holdings
7
HSBC Holdings
United Kingdom
$7.36M +$4.71M +234 +179%
PAMP
8
Polar Asset Management Partners
Ontario, Canada
$6.05M – – –
FTCM
9
Fir Tree Capital Management
New York
$5.06M – – –
HIM
10
HGC Investment Management
Ontario, Canada
$5.04M -$5.04M -250 -50%
WCMNY
11
Westchester Capital Management (New York)
New York
$4.66M – – –
WAM
12
Wolverine Asset Management
Illinois
$4.52M +$443K +22 +11%
RCM
13
Radcliffe Capital Management
Pennsylvania
$4.38M +$423K +21 +11%
CCM
14
Context Capital Management
California
$4.04M – – –
FTCM
15
First Trust Capital Management
Illinois
$4.01M +$463K +23 +13%
WRBC
16
W.R. Berkley Corp
Connecticut
$3.88M +$886K +44 +30%
MI
17
MMCAP International
Cayman Islands
$3.73M – – –
AA
18
AQR Arbitrage
Connecticut
$3.67M – – –
MF
19
Magnetar Financial
Illinois
$3.64M +$3.2M +159 +757%
CSS
20
Cubist Systematic Strategies
Connecticut
$2.72M +$302K +15 +13%
AIMCA
21
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$2.52M – – –
Millennium Management
22
Millennium Management
New York
$2.23M – – –
NAM
23
Nexpoint Asset Management
Texas
$2.2M – – –
CH
24
CVI Holdings
Delaware
$2.09M – – –
WAM
25
Weiss Asset Management
Massachusetts
$2.07M – – –
1
2 3

CERO Hedge Fund Activity: Q3 2022 in Review

65 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q3 2022, worth a combined $159M — up 6.8% from $149M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CERO positions and 5 closed out — a net gain of 13 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $11.8M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $7.51M sold.

  • 65 institutional investors held CERo Therapeutics (CERO) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $159M of CERo Therapeutics stock for Q3 2022, up 6.8% quarter-over-quarter.
  • 18 funds opened new CERo Therapeutics positions in Q3 2022 and 5 closed out, a net change of +13 holders.
  • The largest CERo Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $11.8M added.
  • The largest CERo Therapeutics seller in Q3 2022 was Cantor Fitzgerald, an estimated $7.51M sold.

Based on aggregated 13F filings for Q3 2022.